Why GLP-1 Obesity Drugs Cost ₩500,000 in Korea but Only $70 in the U.S.:The Hidden Political–Economic Mechanics Behind the Price Gap
The stark price difference in GLP-1 obesity drugs between Korea and the U.S. is not a simple currency issue but a complex interplay of politics, economics, and healthcare policy. If you’ve been following global weight-loss trends, you’ve likely heard the names Wegovy and Mounjaro—GLP-1–based medications originally developed for diabetes but now dominating the obesity-treatment market … 더 읽기